

Effects of probiotics on the oral health of patients undergoing orthodontic treatment: a systematic review and meta-analysis

Wener Chen¹, Jianhan Ren¹, Jiachen Li¹, Simin Peng¹, Chengfei Zhang², and Yifan Lin^{1,*}

¹Division of Paediatric Dentistry and Orthodontics, Faculty of Dentistry, The University of Hong Kong, Prince Philip Dental Hospital, 34 Hospital Road, Hong Kong SAR, China

²Division of Restorative Dental Sciences, Faculty of Dentistry, The University of Hong Kong, Prince Philip Dental Hospital, 34 Hospital Road, Hong Kong SAR, China

*Corresponding author. Division of Paediatric Dentistry and Orthodontics, Faculty of Dentistry, The University of Hong Kong, Prince Philip Dental Hospital, No. 34 Hospital Road, Hong Kong SAR, China. E-mail: yflin@hku.hk

Abstract

Background and objective: The effect of probiotics on oral health maintenance in orthodontic patients remains controversial. The aim of the study is to systematically review and assess the effects of probiotics on the oral health and microbiome of patients undergoing orthodontic treatment.

Search methods and selection criteria: Databases including PubMed, Web of Science, Cochrane Library, ClinicalTrials.gov, and ProQuest Dissertations & Theses Global databases were searched from their inception until June 2022. Randomised controlled trials that assessed the effects of probiotics on clinical and microbial outcomes in patients undergoing orthodontic treatment were included.

Data collection and analysis: Data screening and collection were performed, and the risk of bias (RoB) was assessed using the Cochrane RoB 2 tool. The meta-analysis evaluated the effects of probiotics on *Streptococcus mutans* (*S. mutans*) and *Lactobacillus* counts. The quality of the evidence from the meta-analyses was assessed with Grading of Recommendations Assessment, Development and Evaluation (GRADE).

Results: A total of 405 records were identified, of which 15 studies were included in the qualitative synthesis and 4 in the meta-analysis. The patients in all the included studies were treated with fixed orthodontic appliances. Results regarding clinical outcomes were controversial; four out of five studies reported no significant changes in plaque in the probiotic group (P > .05), and two out of three studies reported no significant changes in plaque in the probiotic group (P > .05), and two out of three studies reported no significant changes in the gingival index (P > .05). Regarding microbial outcomes, the meta-analysis results revealed that probiotics significantly increased the likelihood of reducing the abundance of *S. mutans* to below 10⁵ CFU/ml (risk ratio: 2.05 [1.54, 2.72], P < .001) and reduced the likelihood of increasing the abundance of *S. mutans* to beyond 10⁶ CFU/ml (risk ratio: 0.48 [0.28, 0.83], P = .009). However, the quality of evidence according to the GRADE was moderate.

Conclusions and implications: There is insufficient evidence to determine the clinical benefits of probiotics as a supplement for the oral health of patients undergoing orthodontic treatment. However, probiotics may have benefits in reducing the salivary *S. mutans* counts in orthodontic patients.

Registration: PROSPERO (CRD42022366650).

Keywords: probiotics; orthodontic treatment; oral health; oral microorganisms; meta-analysis

Introduction

Orthodontic treatment aims to correct occlusal anomalies and enhance facial aesthetics. However, the use of brackets, elastics, and archwires in fixed orthodontic treatment or the full coverage of teeth by clear aligners pose a significant challenge to maintaining oral hygiene. These orthodontic tools create retentive areas on the tooth surface, favourable for microorganisms and food accumulation. If not timely removed, enamel demineralisation and gingivitis would be developed [1, 2]. Furthermore, multiple studies have demonstrated that patients undergoing fixed orthodontic treatment are susceptible to gingival inflammation and enamel demineralisation [3–5]. Streptococcus mutans (S. mutans) and Lactobacillus acidophilus are the most common colonisers responsible for these consequences [6, 7]. Oral hygiene strategies, including fluoride application, antimicrobial oral rinses, and dietary modifications, have been proposed to prevent the hazards of orthodontic treatment on the tooth structures and gingival tissues [8, 9]. Nevertheless, patients undergoing orthodontic treatment still have a high risk of dental caries and gingivitis.

Probiotics have been proposed as a novel method for oral health maintenance. They refer to 'live microorganisms, when administered in sufficient quantities, provide health benefits to the host', which are available in various forms, such as lozenges, tablets, mouthwashes, and yoghurt [10]. The functions of probiotics are to modulate immunoinflammatory responses by producing bioactive substances, such as bacteriocins or organic acids, and competing with pathogenic

© The Author(s) 2023. Published by Oxford University Press on behalf of the European Orthodontic Society

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

bacteria after adhering to the oral cavity [11]. *Lactobacillus* and *Bifidobacterium* are the most commonly used probiotic genera in orthodontic treatment [12].

Studies have shown that probiotics are beneficial in preventing caries, gingivitis, and halitosis [13–15]. For example, Pahumunto *et al.* reported that the probiotic milk containing *Lactobacillus paracasei* SD1 significantly decreased the development of caries and the number of *S.mutans* in preschoolers as compared to the placebo [16]. Vicario *et al.* assessed the clinical effect of *Lactobacillus reuteri* Prodentis (GUM, Sunstar, Switzerland) in the treatment of periodontitis and found that the mean bleeding on probing and pocket probing depths significantly decreased by 26% and 4.8 mm in the probiotic group, respectively [17]. Lee *et al.* evaluated the effects of *Weissella cibaria* Chonnam Medical University (CMU) (oraCMU; OraPharm, Inc., Seoul, South Korea) on halitosis and found that the volatile sulphur compounds level significantly decreased by 4.81 in the probiotic group [18].

The effects of probiotics on patients undergoing orthodontic treatment remain controversial due to the varied results reported by multiple studies [19-22]. Two published systematic reviews have evaluated the effects of probiotics on the oral health of individuals undergoing orthodontic treatment [23, 24]. Hadj-Hamou et al. systematically reviewed the clinical effects of probiotics on the inflammation of the gingival tissues and the decalcification of the enamel in orthodontic patients. The review included four studies and concluded that supplementation of probiotics did not affect the development of inflammation in the gingivae or decalcification in the enamel [23]. In another review, Pietri et al. assessed nine studies and qualitatively concluded that probiotics had antimicrobial activity against oral pathogenic bacteria [24]. However, neither review employed quantitative syntheses (i.e. meta-analysis) to comprehensively analyse the clinical and microbial effects. Recently, a few more randomised controlled trials (RCTs) assessing the effects of probiotics on patients undergoing orthodontic treatment have emerged as the latest evidence, warranting an updated summary of all the evidence [25–27]. The current study aimed to systematically synthesise data from the available literature to assess the clinical and microbial effects of probiotics on patients undergoing orthodontic treatment. Specifically, the study analysed clinical outcomes including white spot lesions (WSLs) and periodontal indexes (gingival index [GI] and plaque index [PI]), as well as the microbial outcome of salivary bacterial counts.

Materials and methods

Protocol and registration

This systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines. The study protocol has been registered in the PROSPERO database (No.: CRD42022366650). A detailed PRISMA checklist has been appended in Supplementary Table 1.

Eligibility criteria

The study followed the PICOS format, with the following criteria: (i) Population: healthy patients undergoing orthodontic treatment; (ii) Intervention: the use of probiotics; (iii) Comparison: placebo or alternative treatment or no intervention; (iv) Outcomes: clinical outcomes, which comprise periodontal-related indexes (GI and PI) and incidence of WSL, as well as microbial outcomes, which include bacterial counts; and (v) Study design: RCT. Thus, the overall study objective based on the PICOS format was as follows: what are the clinical and microbial effects of probiotics on the oral health of patients undergoing orthodontic treatment? The detailed inclusion and exclusion criteria are listed in Table 1.

Information sources and search strategy

The following electronic databases were searched by two authors (JR and WC) for the relevant literature published from the inception of each database until June 2022: PubMed, Web of Science, Cochrane Library, ClinicalTrials.gov, and ProQuest Dissertations & Theses Global. Furthermore, three major orthodontic journals (*American Journal of Orthodontics and Dentofacial Orthopedics, Angle Orthodontist*, and *European Journal of Orthodontics*) from inception to June 2022 and the reference lists of the selected articles were also hand searched. The following search terms were used: 'probiotic OR probiotics OR *Lactobacillus* OR *Bifidobacterium*' AND 'orthodontic OR orthodontics OR bracket OR brackets OR brace OR braces OR fixed appliance OR fixed appliances OR aligners OR aligner OR Invisalign'.

Study selection and data collection

The shortlisted studies were screened based on the titles and abstracts independently by two authors (WC and JL) to identify the available studies. Full-text papers were retrieved for additional evaluation when the titles and abstracts of the papers lacked adequate information. Disagreements were resolved through discussion with a third author (YL). The Kappa coefficient of agreement between the two reviewers was 0.80 for the screening of titles and abstracts and 0.89 for the screening of full texts. Data from the selected studies were extracted into specific extraction tables, and the following terms were recorded for each study: author names and year of publication, study design, baseline participant characteristics (age, sex ratio, number of participants, and type of orthodontic treatment), study groups, probiotic microorganisms and usage, clinical and microbiological parameters, follow-up duration, and main conclusions.

Risk-of-bias assessment

The risk of bias (RoB) was independently assessed by two authors (WC and YL) using the Cochrane RoB tool for randomised trials (RoB 2.0). The quality assessment criteria spanned five domains: randomisation process, deviations from intended interventions, missing outcome data, outcome measurement, and reported result selection. The RoB in a study was classified as 'low' if all the domains were judged to have a low-risk bias; 'some concerns' if at least one domain was judged to have some concern bias but not a high RoB for any domain; and 'high RoB' if at least one domain was judged to have a high RoB or included some concerns for multiple domains.

Summary measures and quantitative synthesis of the results

Using the RevMan software (Review Manager version 5.3; Copenhagen: the Nordic Cochrane Centre, the Cochrane Collaboration, 2014), a meta-analysis of dichotomous outcomes was performed to compare the number of probiotictreated patients with those in the control group with high (>10⁶ CFU/ml) and low (<10⁵ CFU/ml) *S. mutans* and Table 1. Eligibility criteria for study selection.

Category	Inclusion criteria	Exclusion criteria
Study design	Randomised controlled trials	Studies that are not randomised controlled trials
Participants	Healthy patients undergoing orthodontic treatment	Patients with craniofacial anomalies, periodontitis, and systemic or other medical conditions
Interventions	Use of probiotics	Use of non-probiotics
Comparisons	Placebo Alternative treatment No intervention	Studies without a control group
Outcomes	Clinical outcomes: periodontal indexes (GI and PI) and incidence of WSLs Microbial outcome: bacterial counts	Other outcomes

GI, gingival index; PI, plaque index; WSLs, white spot lesions.

Lactobacillus counts after treatment. Studies with a 'high RoB' were excluded from the meta-analysis. The risk ratios and 95% confidence intervals were calculated and displayed in forest plots. A *P* value < .05 indicated statistical significance. The I^2 test was performed to assess the heterogeneity of the studies. The fixed effects model was applied if the I^2 was < 50, whereas the random effects model was used if the I^2 was \geq 50. Data that could not be analysed quantitatively were evaluated descriptively. Furthermore, due to insufficient data and variations in the included studies, subgroup analyses, analyses for 'small-study effects', and assessment of publication bias could not be carried out. The quality of the evidence from the meta-analyses was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) method [28].

Results

Study selection

The study flow is depicted in Fig. 1. The systematic search identified 579 records and 405 studies were screened after excluding duplicates. A total of 350 studies were excluded after screening for titles and abstracts. The remaining 55 studies were further evaluated through full-text screening for eligibility. Finally, a total of 15 studies were included in the qualitative synthesis (Fig. 1).

General characteristics of the included studies

The general characteristics of the 15 studies are presented in Table 2. All of these studies were RCTs that were published between 2009 and 2022 and used a double-blind (10 RCTs), parallel-group (13 RCTs), and cross-over (2 RCTs) design. The participant age ranged between 8 and 35 years, and the sample size ranged between 24 and 85. All of the included studies had test and control groups for comparison. Although we had no restrictions in terms of the type of orthodontic appliance used, all of the included studies used fixed ortho-dontic appliances.

The PI was recorded in five studies [20, 21, 26, 29, 30]. The GI or modified GI was recorded in three studies [20, 21, 31]. The incidence of WSL was assessed in one study [32]. The *S. mutans* and/or *Lactobacillus* counts were evaluated in the plaque or saliva of patients in 11 studies [21, 22, 25–27, 30, 32–36].

Risk-of-bias assessment

The results of the RoB 2.0 assessment of the selected studies are presented in Fig. 2. Six studies were considered as 'low RoB' [20, 26, 27, 32, 33, 36] for all the key domains. Six studies were considered to have 'some concerns' [22, 25, 30, 31, 34, 35], whereas three studies [19, 21, 29] were considered to have a 'high RoB'.

Characteristics related to probiotic administration

The durations of the probiotic interventions ranged from 14 days to 17 ± 6.8 months, and the most typical intervention period was 14 days [22, 25, 29, 33, 36]. The measurements were taken at the beginning before probiotic administration and immediately after administration. Four studies examined the effects of probiotic treatment by measuring participants both before and after treatment, as well as at follow-up periods ranging from 28 days to 3 months after treatment cessation [20, 26, 30, 31].

Regarding probiotic delivery vehicles, four studies used mouthwash [19, 21, 25, 27], six studies used lozenges [20, 26, 29–32], three studies used yoghurt [22, 33, 36], and two studies used toothpaste [34, 35]. In terms of probiotic species, most studies used a mix of probiotic species, whereas five studies used a single probiotic species [20, 21, 25, 33, 36]. At the genus level, *Lactobacillus* species were most commonly used [19, 21, 22, 25–27, 29–32], followed by *Streptococcus* [20, 22, 26, 30, 31].

Main outcomes of the included studies

Clinical changes

The clinical outcome parameters used to assess the effects of probiotics on the oral health of the patients undergoing orthodontic treatment were PI, GI, and incidence of WSLs. Due to the high level of heterogeneity in the clinical examinations and parameters used, quantitative synthesis of the clinical changes could not be conducted.

Of the five studies that recorded the PI, four reported no significant changes between the probiotic and placebo groups (P > .05) [20, 26, 29, 30]. In contrast, Shah *et al.* [21] reported a considerably decreased PI in the probiotic group compared to the control group without intervention (P < .05). Specifically, the mean PI decrease was 0.6 in the probiotic group, which was considerably greater than the 0.03




Figure 1. PRISMA flow diagram of the search results from the electronic databases.

decrease in the control group. In terms of the GI, Benic *et al.* and Habib [20, 31] found that probiotics did not affect the GI significantly (P > .05); however, Shah *et al.* [21] reported a significant reduction of 0.87 in GI of the probiotic group (P< .05). In terms of the incidence of WSLs, Gizani *et al.* [32] found no significant differences between the probiotic and placebo groups. At debonding, no new lesion was found in 22 out of 42 patients in the probiotic group and 26 out of 43 in the placebo group.

Microbial changes

Of the 11 studies that assessed S. mutans counts in the saliva or plaque of patients, five [21, 22, 34-36] revealed that probiotic use can significantly reduce S. mutans counts (P < .05). For instance, Cildir et al. [36] demonstrated that the percentage of subjects with high S. mutans counts dropped from 63% to 21% after 14 days consumption of probiotic yoghurt. Similarly, Shah *et al.* [21] observed a significant decrease in *S*. mutans counts from 7.1×10^4 CFU/ml to 1.1×10^3 CFU/ml after 28 days of using probiotic mouthwash. Of the six studies [27, 30, 32–34, 36] that evaluated *Lactobacillus* counts in the saliva or plaque of patients, Alp and Baka [34] and Gizani et al. (32) found significant reductions in Lactobacillus counts (P < .05). Specifically, Alp and Baka [34] reported that the percentage of subjects with a Lactobacillus level of 10⁶ or greater at the beginning of the study decreased from 13.3% to 0% in the probiotic toothpaste group. In the study by Gizani et al., [32] such proportion decreased from 40.5% to 21.4% in the probiotic lozenge group. Goyal et al. [19] reported that the use of probiotic mouthwashes significantly decreased the levels of Porphyromonas gingivalis by 1.6×10^6 CFU/ml (P < .05). Conversely, Habib [31] assessed the levels of other periodontal pathogens (P. intermedia, C. rectus, and F. nucleatum) in the subgingival plaque and found no significant changes (P > .05).

Meta-analysis

Of the 15 studies, three studies classified as having a 'high RoB' were excluded from the meta-analysis [19, 21, 29]. Finally, four studies [22, 32, 34, 36] were included in a dichotomous meta-analysis as information on the proportion of patients with low, medium, or high counts of salivary S. mutans or Lactobacillus could be extracted. These RCTs used a chair-side test for evaluating the levels of S. mutans or Lactobacillus. In the first meta-analysis for low S.mutans counts ($<10^5$ CFU/ml), the results showed that 79 (69.3%) of the 114 individuals who used probiotics had low S.mutans counts ($<10^5$ CFU/ml), compared to 38 (33.6%) of the 113 participants in the placebo group. This finding indicates that probiotics significantly increased the likelihood of reducing the abundance of S. mutans to $<10^5$ CFU/ml (RR: 2.05 [1.54, 2.72]; P < .001; $I^2 = 33\%$) (Fig. 3a). In the second metaanalysis for high S.mutans counts (>106 CFU/ml), 13 (11.4%) of the 114 individuals in the probiotic group exhibited high S.mutans counts (>10⁶ CFU/ml), compared to 29 (25.7%) of the 113 patients in the control group. The supplementation of probiotics significantly reduced the likelihood of increasing this abundance to >10⁶ CFU/ml (RR: 0.48 [0.28, 0.83]; P = .009; $I^2 = 5\%$) (Fig. 3b). In the third and fourth meta-analyses for low and high Lactobacillus counts, patients that used (n = 47) and did not use (n = 37) probiotics exhibited low Lactobacillus counts (<105 CFU/ml), and 11 patients in the probiotic group and 17 patients in the control group showed high Lactobacillus counts (>106 CFU/ml). No significant differences were observed in the abundance of Lactobacillus at either $<10^5$ CFU/ml (RR: 1.28 [0.93, 1.77]; P = .13; $I^2 =$ 0%) (Fig. 4a) or >10⁶ CFU/ml (RR: 0.67 [0.34,1.30]; P = .24; $I^2 = 0\%$) (Fig. 4b). Quantitative analyses for other outcome parameters could not be conducted due to insufficient data and the diverse measuring methods. The quality of evidence on the microbial measures according to the GRADE approach was moderate due to limited sample sizes (Supplementary Table 2).

Discussion

Probiotics suppress the growth of pathogenic microorganisms by producing antimicrobial compounds and competing for adhesion sites with pathogens [11], offering an alternative for the prevention and treatment of caries and gingivitis in patients undergoing orthodontic treatment [23, 24]. This systematic review and meta-analysis aimed to summarise the recently published data and evaluate whether supplementation with probiotics is beneficial to the oral health of patients undergoing orthodontic treatment. The outcome measurements include periodontal indexes, incidence of WSLs, and bacterial counts, which are the most commonly affected oral health-related measures during orthodontic treatment.

In general, the clinical effectiveness of probiotics for orthodontic patients is conflicting. Four studies reported no significant changes in PI in the probiotic group [20, 26, 29, 30], and two demonstrated that probiotics did not significantly reduce GI [20, 31] However, Shah *et al.* [21] reported that the probiotic group's build-up of plaque and gingival inflammation were significantly decreased. One study assessing the WSLs reported that there was no significant difference in the incidence of WSLs between the probiotic

Main conclusions	No significant dif- ference in <i>S. mutans</i> counts between the probiotic group and the placebo group.	No significant change in PI and in <i>S. mutans</i> DNA levels in the saliva and plaque in the probiotic group during the interven- tion and follow-up periods.	A significant re- duction in salivary <i>S. mutans</i> levels was recorded after probiotic yoghurt ingestion.	The probiotic group had significantly reduced PI, GI, and <i>S.mutans</i> counts as compared to the control group with- out intervention.
Additional follow-up (no intervention)	~	28 days		
Intervention duration	14 days	28 days	14 days	28 days
Probiotic usage	Twice daily	Two lozenges two times daily for the first 7 days, followed by two lozenges once a day for the next 21 days	daily	Twice daily
Probiotic microorganism	L. plantarum (10 ⁸ CFU/30 mg)	Probiotic complex: S. salivarius K12 and five pro- biotic strains of the genus Lactobacillus $(3 \times 10^5 \text{CFU})$ lozenge)	(i) L. acid- ophilus 20 \times 10 ⁷ CFU/g, Bifidobacteria 5.4 \times 10 ⁷ CFU/ g-yoghurt (ii) L.acidophilus \times 10 ⁶ CFU/g, S.thermophiles 35 \times 10 ⁴ CFU/g- Indian curd	L. sporogenes (2 × 10 ⁸ CFU/g)
Study outcomes	S. <i>mutans</i> counts in plaque	PI, <i>S.mutans</i> DNA levels in plaque and saliva	S. <i>mutans</i> scores in plaque and saliva	PI, GI, S. <i>mutans</i> counts in saliva
Study groups	Test group: pro- biotic mouthwash (n = 13) Control group: (i) placebo mouth- wash $(n = 13)$ (ii) sodium fluoride mouthwash $(n =$ 12)	Test group: Lorodent probiotic lozenge $(n = 29)$ Control group: placebo lozenge $(n = 29)$	Test group: (i) probiotic yog- hurt $(n = 9)$ (ii) Indian curd with probiotic bac- teria $(n = 9)$ Control group: placebo yoghurt (n = 9)	Test group: pro- biotic mouthwash (n = 10) Control group: (i) 0.2% chlorhexi- dine mouthwash $(n = 10)$ (ii) no intervention (n = 10)
Orthodontic treatment	Fixed orthodontic treatment	Fixed orthodontic treatment	Fixed orthodontic treatment	NR
Participants (number and gender)	N = 38 (14M, 24F)	N = 58 (25M, 33F)	N = 27 (14M, 13F)	N = 30 (M:F) NR
Age range (mean)	12–20 (NR)	11-18 (15.7 ± 1.7) 1.7)	8–15 (NR)	NR
Study design	RCT, parallel	RCT, double-blind, parallel	RCT, double-blind, parallel	RCT, parallel
Author, year	Dadgar <i>et al.</i> , 2021 [25]	Ebrahim <i>et al.</i> , 2022 [26]	Megha <i>et al.</i> , 2019 [22]	Shah <i>et</i> <i>al.</i> , 2019 [21]

Table 2. Summary of the 15 studies included.

Table 2. (Table 2. Continued									
Author, year	Author, Study design Age ear rang (mea	Age range (mean)	Participants (number and gender)	Participants Orthodontic Study groups (number treatment and gender)	Study groups	Study outcomes	Probiotic microorganism	Probiotic usage	Intervention duration	
Cildir <i>et</i> F <i>al.</i> , 2009 c [36] c	RCT, 12–16 double-blind, (14 ± crossover 1.2)	12-16 (14 ± 1.2)	N = 24 (8M, 16F)	Fixed orthodontic treatment	Test group: pro- biotic yoghurt (<i>n</i> = 12) Control group: placebo yoghurt (<i>n</i> = 12)	<i>S. mutans</i> and <i>Lacto-</i> <i>bacillus</i> scores in saliva	B. animalis subsp. Lactis DN-173010 (2 × 10 ⁸ CFU/g)	200g once daily	T1. 7 days (run-in) T2.14 days (interven- tion) T3. 42 days (wash-out) T4.14 days (interven- tion)	
Pinto <i>et</i> <i>al.</i> , 2014 [33]	RCT, 10–30 double-blind, (15) crossover	10–30 (15)	N = 26 (10M, 16F) (overall	Fixed orthodontic treatment	Test group: pro- biotic yoghurt ($n = 15$)	Total cultiv- able micro- organisms	B. animalis subsp. Lactis DN-173010	200g once daily	T1. 7 days (run-in) T2.14 days (interven- tion)	

	A statistically sig- nificant reduction of salivary <i>Smutans</i> in the probiotic group. No significant alter- ations of the salivary <i>Lactobacilus</i> counts were observed.	No difference be- tween the yogurt containing probiotic and the control yogurt for any of the studied variables.	No differences in the incidence of WSL and <i>S.mutans</i> counts between the groups at debonding. The levels of salivary <i>Lactobacillus</i> were significantly reduced in both groups.	No significant differences in the probiotic group for any variables.
follow-up (no intervention)	~	~	~	~
	T1. 7 days (run-in) T2.14 days (interven- tion) T3. 42 days (wash-out) T4.14 days (interven- tion)	T1. 7 days (run-in) T2.14 days (interven- tion) T3. 28 days (wash-out) T4.14 days (interven- tion)	17 ± 6.8 months	14 days
usage	200g once daily	200g once daily	One lozenge once daily	One lozenge/ bottle once daily
microorganism	B. animalis subsp. Lactis DN-173010 (2 × 10 ⁸ CFU/g)	B. animalis subsp. Lactis DN-173010	Two strains of the probiotic bacterium <i>L.</i> <i>reuteri</i> (DSM 17938 and ATCC PTA 5289) (10 ⁸ live bac- teria of each strain)	 (i) <i>L. reuteri</i> (200 million live bacteria/ lozenge- lozenge (ii) <i>L. casei</i> strain <i>Shirota</i> (6.5 million viable cells of LcS/bortle)- drink
outcomes	<i>S. mutans</i> and <i>Lacto-</i> <i>bacillus</i> scores in saliva	Total cultiv- able micro- organisms counts, S. <i>mutans</i> and <i>Lactobacilli</i> counts in plaque and saliva	WSL, S. <i>mutans</i> and Lactobacilus scores in saliva	Id
	Test group: pro- biotic yoghurt (n = 12) Control group: placebo yoghurt (n = 12)	Test group: pro- biotic yoghurt (n = 15) Control group: placebo yoghurt (n = 15)	Test group: pro- biotic lozenge (<i>n</i> = 42) Control group: placebo lozenge (<i>n</i> = 43)	Test group: (i) probiotic lozenge (n = 10) (ii) probiotic drinks (n = 10) Control group: pla- cebo $(n = 10)$
treatment	Fixed orthodontic treatment	Fixed orthodontic treatment	Fixed orthodontic treatment	Fixed ortho- dontics treatment
(number and gender)	N = 24 (8M, 16F)	<i>N</i> = 26 (10M, 16F) (overall 30, 4 were excluded due to non-attend- ance)	N = 85 (29M, 56F)	N = 30 (M:F) NR
range (mean)	12-16 (14 ± 1.2)	10–30 (15)	NR (15.9 ± 3.9)	18–25 (NR)
	RCT, double-blind, crossover	RCT, double-blind, crossover	RCT, double-blind, parallel	RCT, parallel
year	Cildir <i>et</i> <i>al.</i> , 2009 [36]	Pinto <i>et</i> <i>al.</i> , 2014 [33]	Gizani <i>et</i> <i>al.</i> , 2016 [32]	Kohar <i>et</i> <i>a</i> l., 2015 [29]

Main conclusions

Additional

Main conclusions	A statistically signifi- cant decrease was observed in the sal- ivary <i>S mutans</i> and <i>Lactobacillus</i> levels in the probiotic groups.	The levels of <i>P. gingualis</i> were sig- nificantly decreased with probiotic mouthwash.	PI and GI scores were not signifi- cantly influenced by the probiotic use during the interven- tion and follow-up periods.	No significant differ- ences in <i>S. mutans</i> and <i>Lactobacillus</i> counts were found.	The probiotic groups caused a sig- nificant decrease in the <i>S.mutans</i> levels in the plaque.
Main co	A statist cant dec observe ivary S Lactobe in the p groups.	The levels of <i>P</i> gingivalis were nificantly decre with probiotic mouthwash.	PI and C were no cantly ir by the p during t tion and periods.	No sign ences in and <i>La</i> (counts v	The probiotic groups caused nificant decree the <i>S.mutans</i> l in the plaque.
Additional follow-up (no intervention)	~	~	3 months	~	~
Intervention duration	42 days	6 months	1 month	21 days	30 days
Probiotic usage	(i) 2 × 100 ml kefir once daily (ii) Twice daily (tooth- paste)	Twice daily	One lozenge twice daily	Twice daily	 (i) 200 mg curd once daily (ii) Twice daily (tooth- paste)
Probiotic microorganism	 (i) mixture of lactic acid bac- teria culture- kefir (ii) Bacteri- ocin extracted from lactic acid bacteria- toothpaste 	L. reuteri (0.1 billion CFU), L. rhamnosus (0.1 billion CFU), B.longum (0.06 billion CFU), B. bifdum (0.1 billion CFU) per gram	<i>S. salivarius</i> M18 (3.6 × 10 ⁹ CFU/lozenge)	L. reuteri DSM 17938(>1 × 10 ⁸ CFU/5 drops), L. reuteri ATCC PTA 5289(>1 × 10 ⁸ CFU/5 drops)	 (i) L. acidophilus- SD 5221 (10° CFU/200g)- curd (ii) Bacteri- ocin extracted from lactic acid bacteria- toothpaste toothpaste
Study outcomes	<i>S. mutans</i> and <i>Lacto-</i> <i>bacillus</i> levels in saliva	<i>P.gingivalis</i> levels in subgingival plaque	PI and GI	<i>S. mutans</i> and <i>Lacto-</i> <i>bacillus</i> counts in saliva	<i>S. mutans</i> levels in plaque
Study groups	Test group: (i) pro- biotic kefir ($n = 15$) (ii) probiotic tooth- paste ($n = 15$) Control group: no probiotic treatment ($n = 15$)	Test group: pro- biotic mouthwash (n = 10) Control group: (i) amine fluoride mouthwash $(n =$ 10) (ii) no intervention (n = 10)	Test group: probiotic lozenge (n = 32) Control group: placebo lozenge $(n = 32)$	Test group: probiotic mouth rinse $(n = 14)$ Control group: placebo mouth rinse $(n = 14)$	Test group: (i) probiotic curd (n = 20) (ii) probiotic tooth- paste $(n = 20)$ Control group: no probiotic treat- ment $(n = 20)$
Orthodontic treatment	Fixed orthodontic treatment	Fixed orthodontic treatment	Fixed orthodontic treatment	Fixed orthodontic treatment	Fixed orthodontic treatment
Participants (number and gender)	N = 45 (18M, 27F)	N = 30 (M:F) NR	N = 64 (23M, 41F)	N= 28 (14M, 14F)	N = 60 (18M, 42F)
Age range (mean)	12-17 (14.43 \pm 1.93)	15-35 (NR)	10-30 (14.9 ± 3.2)	NR (17.3 ± 1.1)	14-29 (20)
Study design	RCT, parallel	RCT, parallel	RCT, triple- blind, par- allel	RCT, double-blind, parallel	RCT, double-blind, parallel
Author, year	Alp and Baka, 2018 [34]	Goyal <i>et</i> <i>al.</i> , 2019 [19]	Benic <i>et</i> <i>al.</i> , 2019 [20]	Alforaidi <i>et al.</i> , 2021 [2 7]	Jose et al., 2013 [35]

Table 2. Continued

Author,Study designAgeParticipantsCuthodonticStudy groupsCuthodonticStudy groupsMain contractionAdditionalMain contractionAddit	Table 2. C	Table 2. Continued										
RCT,11–18 $N = 58$ FixedTest group: pro- biotic lozenge (n)Modified GI, statinariusStatinarius two timesTwo lozenges28 days28 daysparallel ± 1.70) (15.69) $(25M, 33F)$ orthodontic biotic lozenge (n)periodontal treatment $K12$ and five two timestwo times28 days28 daysparallel ± 1.70)treatment $= 29$)pathogens pickelo lozenge (n)probiotic subgingvaldaily for the first 7 days, plaquefirst 7 days, two lozenges28 days28 daysRCT,11–18N = 58Fixedreatment $= 29$)plaquecillustwo times28 daysRCT,11–18N = 58FixedTest group: pro- lozengePl, SS alitariustwo times28 daysdouble-blind,(15.69)25M, 33F)orthodontic biotic lozenge (nPl, SS alitariusTwo lozenges28 daysdouble-blind, (15.69) 25M, 33F)orthodontic biotic lozenge (nPl, SS salivariusTwo lozenges28 daysparallel ± 1.70) ± 1.70 SS salivarius and gents Lactoda- for the placebo lozenge (nPl, SS salivarius gents Lactoda- for the first 7 days,28 daysparallel ± 1.70 ± 1.70 SS salivarius and gents Lactoda- for the first 7 days,28 daysparallel ± 1.70 ± 2.9 S salivarius and gents Lactoda- for the for the first 7 days,29 daysparall	Author, year		Age range (mean)		Orthodontic treatment	Study groups	Study outcomes	Probiotic microorganism	Probiotic usage	Intervention duration	Additional follow-up (no intervention)	Main conclusions
RCT, 11–18 $N = 58$ Fixed Test group: pro- parallel ± 1.70 (25M, 33F) orthodontic biotic lozenge (n mutans and K12 and five two times parallel ± 1.70) ± 1.70 treatment $= 29$) Lactobacil- probiotic daily for the Control group: lus levels in strains of the first 7 days, placebo lozenge (n saliva and genus Lactoba- probiotic daily for the control group: lus levels in strains of the first 7 days, plaque CFU/lozenge) once a day for the next 21 days	Habib, 2016 [31]	RCT, double-blind, parallel	11-18 (15.69 ± 1.70)	N = 58 (25M, 33F)	Fixed orthodontic treatment	Test group: pro- biotic lozenge (<i>n</i> = 29) Control group: placebo lozenge (<i>n</i> = 29)	Modified GI, periodontal pathogens levels in subgingival plaque	S. salivarius K12 and five probiotic strains of the genus Lactoba- cillus (1 billion CFU/ lozenge)	Two lozenges two times daily for the first 7 days, followed by two lozenges once a day for the next 21 days	28 days	28 days	The probiotic lozenge did not significantly reduce periodontal patho- gens or GI during the intervention and follow-up periods.
	Jivraj, 2015 [30]	RCT, double-blind, parallel	11-18 (15.69 ± 1.70)	N = 58 (25M, 33F)	Fixed orthodontic treatment	Test group: pro- biotic lozenge (<i>n</i> = 29) Control group: placebo lozenge (<i>n</i> = 29)	PI, <i>S.</i> <i>mutans</i> and <i>Lactobacil-</i> <i>lus</i> levels in saliva and subgingival plaque			28 days		No significant changes in <i>S. mutans</i> and <i>Lactobacil-</i> <i>lus</i> levels in the probiotic group during the inter- vention period and follow-up period.

RCT, randomised controlled trial; NR, not reported; M, male; F, female; PI, plaque index; GI, gingival index; WSL, white spot lesion; S., Streptococcus; L., Lactobacillus; B., Bifidobacterium; P., Porphyromona.

and placebo groups at debonding [32]. The variations in the probiotic administration vehicle, concentration, strains, and intervention duration could explain these controversial results.

	<u>D1</u>	<u>D2</u>	<u>D3</u>	<u>D4</u>	<u>D5</u>	Overall
Dadgar et al., 2021	•	+	+	+	+	!
Ebrahim et al., 2022	+	+	+	+	+	+
Megha et al., 2019	•	+	+	+	!	!
Shah et al., 2019	1	1	+	•	+	-
Cildir et al., 2009	+	+	+	+	+	+
Pinto et al., 2014	+	+	+	+	+	+
Gizani et al., 2016	+	+	+	+	+	+
Kohar et al., 2015	1	!	+	•	1	-
Alp and Baka, 2018	1	1	+	+	+	!
Goyal et al., 2019	1	!	+	•	+	-
Benic et al., 2019	+	+	+	+	+	+
Alforaidi et al., 2021	+	+	+	+	+	+
Jose et al., 2013	!	+	+	+	!	!
Habib, 2016	!	+	+	+	+	!
Jivraj, 2015	!	+	+	+	+	!

Figure 2. Quality assessment of the RCTs (RoB 2.0). Symbol: green (+): low RoB; yellow (!): some concerns of bias; red (-): high RoB. Domains: D1: Bias arising from the randomisation process; D2: Bias due to deviations from intended intervention; D3: Bias due to missing outcome data; D4: Bias in measurement of the outcome; D5: Bias in selection of the reported result.

Concerning the administration methods, probiotics were found to be positive in most studies when used in mouth rinses and dairy products, including yoghurt and curd [19, 21, 22, 27, 35, 36]. Dairy products such as milk and yoghurt are generally regarded as effective probiotic administration vehicles. These products include calcium phosphate, ammonia, and casein, improving enamel remineralisation, raising plaque-PH, and preventing bacterial cells from adhering to the teeth [37]. According to a systematic review and meta-analysis, the dairy products used in 14 of the 20 trials substantially reduced the S. mutans levels [38]. The use of mouth rinses is efficient since these can reach the tooth surface easily, including around the brackets and archwires, leading to the effective colonisation of the probiotic microorganisms in the oral cavity [21]. By contrast, six studies that demonstrated no positive effects of probiotics used lozenges as the probiotic carrier, suggesting lozenges may not be effective vehicles in promoting oral health [20, 26, 29-32].

The optimal strains and concentrations of probiotics for use in oral health maintenance are yet to be clarified. A large number of current dental research articles used probiotic doses ranging from 10⁸ to 10⁹ CFU [32, 39, 40]. Most of the studies included in this systematic review used probiotic doses within this range, however, in one study, Ebrahim et al. used a concentration of 105 CFUs/lozenge and failed to observe any clinically detectable effects on plaque build-up [26]. The authors considered that the lack of significant changes could be due to the low concentration of probiotics. Apart from variations in concentrations, there was also a diversity of probiotic bacterial species. Lactobacillus and Bifidobacterium species are the most common probiotic microorganisms used for oral health, with most of the studies in this review using these two species [19, 21, 22, 25–27, 29–33, 35, 36]. Similar to probiotics used in the gastrointestinal system, a combination

^		Probio	otic	Control Risk Ratio		Risk Ratio				
Α	Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl		M–H, Fixed, 95% Cl	
	Alp 2018 1	12	15	5	15	12.9%	2.40 [1.12, 5.13]		— —	
	Alp 2018 2	13	15	5	15	12.9%	2.60 [1.24, 5.46]			
	Cildir 2009	19	24	12	24	30.9%	1.58 [1.01, 2.48]			
	Gizani 2016	22	42	16	43	40.7%	1.41 [0.87, 2.28]		+∎-	
	Megha 2019 1	9	9	0	8	1.4%	17.10 [1.15, 253.80]			→
	Megha 2019 2	4	9	0	8	1.4%	8.10 [0.50, 130.50]			→
	Total (95% CI)		114		113	100.0%	2.05 [1.54, 2.72]		•	
	Total events	79		38						
	Heterogeneity: Chi ² =	7.44, df	= 5 (P	= 0.19);	$I^2 = 33$	%		0.01	0.1 1 10 10	00
	Test for overall effect	Z = 4.93	8 (P < 0).00001)				0.01	Favors [control] Favors [probiotic]	0




Figure 3. Forest plots depicting the comparison between the probiotic and control groups after treatment: (a) S. mutans $<10^{5}$ CFU/ml; (b) S. mutans $>10^{6}$ CFU/ml.




Figure 4. Forest plots depicting the comparison between the probiotic and control groups after treatment: (a) Lactobacillus <10⁵ CFU/ml; (b) Lactobacillus >10⁶ CFU/ml.

of probiotic bacterial strains may exert a synergistic effect against oral disorders [41]. Alp and Baka, Goyal et al., and Megha et al. used a mixture of probiotic bacterial strains and observed a significant decrease in the pathogen levels [19, 22, 34]. By contrast, the Lorodent probiotic complex, which contains five Lactobacillus strains, exhibited no positive effects in reducing plaque accumulation and S. mutans counts in patients undergoing orthodontic treatment [26, 30, 31]. It is crucial to consider the unique orthodontic environment when determining the optimal probiotic concentration and strain for patients undergoing orthodontic treatment. Oral biofilms in these individuals tend to be thicker and more pathogenic compared to those in the general population, primarily due to the adverse effects of fixed orthodontic appliances on oral hygiene [42]. Previous research has revealed that the S. mutans counts were four times higher in patients undergoing orthodontic treatment than in the general population [43]. Therefore, future studies are still required to determine the optimal species and concentrations of probiotics to be used as a supplement for orthodontic patients.

In terms of the microbiological outcomes, five studies [21, 22, 34–36] concluded that probiotic use can significantly reduce S. mutans counts in the saliva or plaque of patients, whereas the other six studies reported contradictory results [25-27, 30, 32, 33]. Alp and Baka [34] and Gizani et al. [32] found significant decreases in the Lactobacillus counts in the saliva of patients in the probiotic group, whereas the other four RCTs showed no considerable alternations [27, 30, 33, 36]. The possible reasons for the contradictory microbiological outcomes could be the clinical heterogeneity factors mentioned before. An additional reason is the different methods used to assess the microorganism counts. There are three methods for assessing microorganism counts: traditional plate counting, real-time quantitative polymerase chain reaction, and chair-side test kits. The chair-side tests correspond well with traditional laboratory methods, are simple to handle in clinical settings, and are thus extensively used

in evaluating bacterial levels [32, 36, 44]. The four studies included in the meta-analysis used the chair-side test for evaluating the levels of S. mutans or Lactobacillus [22, 32, 34, 36]. A meta-analysis was conducted on these four studies that summarised the number of patients with different levels of S. mutans or Lactobacillus before and after probiotic use. The results showed that when the probiotic and control groups were compared after treatment, the probiotic group had more patients with low salivary S. mutans counts (<10⁵ CFU/ml) and fewer patients with high counts (>10⁶ CFU/ml); however, no such significant effects were observed for Lactobacillus. The results suggested that probiotics significantly increased the likelihood of reducing the abundance of S. mutans to below 105 CFU/ml and reduced the likelihood of increasing the abundance of S. mutans to beyond 106 CFU/ml. This result corroborates those of other meta-analyses conducted in the general population without orthodontic treatment: three meta-analyses concluded that probiotic therapy in the general population may decrease the S. mutans counts but have no effects on Lactobacillus [38, 45, 46]. Based on these results, probiotics might have a potential preventive effect on dental caries by reducing the S. mutans counts in saliva. However, whether this reduction in S. mutans counts in orthodontic patients has any clinical significance remains to be elucidated. In addition, Lactobacillus counts were not significantly changed when comparing the probiotic and control groups at the end of the intervention. The reason underlying the nonsignificant differences in the Lactobacillus counts may be explained by the fact that some of the studies used Lactobacillus as the probiotic strain, which may have masked the ultimate bacterial counts [38].

It is worth noting that although the probiotic strains varied in the current analysis, previous research suggested that some observed probiotic effects are traits shared by multiple probiotic species rather than just a few well-studied strains [47, 48]. For instance, Caglar and colleagues conducted several studies examining the change in saliva *S. mutans* counts Downloaded from https://academic.oup.com/ejo/advance-article/doi/10.1093/ejo/cjad046/7238860 by University of Hong Kong user on 10 August 2023

after the consumption of various probiotics, including *Bifidobacterium lactis* Bb-12, *Lactobacillus reuteri* ATCC 55730 and ATCC PTA 5289, *Bifidobacterium* DN-173010, using different delivery methods (chewing gum, yoghurt, water, and tablets) [49–51]. The results demonstrated a significant decrease in *S. mutans* counts in all studies, independent of the probiotic strain used. Therefore, the current study focuses on the overall effects rather than differentiating between specific probiotic species, thereby encompassing a broader understanding of the collective impact of probiotics in orthodontic treatment.

Limitations

Despite a comprehensive search strategy, there is a shortage of high-quality RCTs with adequate sample size to make clinical recommendations. Current studies lack standardisation in their probiotic protocols, resulting in variations in strains, concentrations, intervention durations, and follow-up durations. Additionally, subgroup or correlation analyses were not possible due to the heterogeneities between the studies and the limited sample sizes. Owing to these methodological shortcomings, the conclusions should be generalised with caution.

Conclusion

There is insufficient evidence to determine the clinical benefits of probiotics on the oral health of patients undergoing orthodontic treatment. Probiotics may have potential benefits in reducing salivary *S. mutans* counts; however, whether this reduction in *S. mutans* counts has any clinical significance remains to be elucidated. Future studies should be conducted to determine the optimum delivery system, appropriate probiotic strains, and effective concentrations and should have a longer follow-up duration. Moreover, the effects of probiotics on the oral health of patients undergoing orthodontic treatment with other appliances, such as clear aligners and lingual appliances, should also be explored.

Author contributions

Wener Chen (Data curation [equal], Formal analysis [equal], Methodology [equal], Visualization [lead], Writing—original draft [lead]), Jianhan Ren (Data curation [equal], Methodology [equal]), Jiachen Li (Data curation [equal], Methodology [equal]), Simin Peng (Supervision [supporting], Writing—review & editing [supporting]), Chengfei Zhang (Supervision [supporting], Writing—review & editing [supporting]), and Yifan Lin (Conceptualization [lead], Data curation [lead], Funding acquisition [lead], Investigation [Lead], Methodology [lead], Project administration [lead], Resources [lead], Supervision [lead], Writing—review & editing [lead]).

Conflict of interest

All authors have no conflicts of interest to declare.

Ethics approval

No ethical approval was required for this systematic review and meta-analysis.

Funding

This work was supported by the Health and Medical Research Fund of Hong Kong (grant number 19201421).

Data availability

The data underlying this article will be shared on reasonable request to the corresponding author.

Supplementary material

Supplementary material is available at *European Journal of Orthodontics* online.

References

- Guo R, Lin Y, Zheng Y et al. The microbial changes in subgingival plaques of orthodontic patients: a systematic review and metaanalysis of clinical trials. BMC Oral Health 2017;17:90. https:// doi.org/10.1186/s12903-017-0378-1
- Mummolo S, Nota A, Albani F et al. Salivary levels of Streptococcus mutans and Lactobacilli and other salivary indices in patients wearing clear aligners versus fixed orthodontic appliances: an observational study. PLoS One 2020;15:e0228798. https://doi. org/10.1371/journal.pone.0228798
- Tufekci E, Dixon JS, Gunsolley JC *et al*. Prevalence of white spot lesions during orthodontic treatment with fixed appliances. *Angle Orthod* 2011;81:206–10. https://doi.org/10.2319/051710-262.1
- Boke F, Gazioglu C, Akkaya S et al. Relationship between orthodontic treatment and gingival health: a retrospective study. Eur J Dent 2014;8:373–80. https://doi.org/10.4103/1305-7456.137651
- Lucchese A, Gherlone E. Prevalence of white-spot lesions before and during orthodontic treatment with fixed appliances. *Eur J* Orthod 2013;35:664–8. https://doi.org/10.1093/ejo/cjs070
- Davis SM, Plonka A, Fulks BA *et al.* Consequences of orthodontic treatment on periodontal health: clinical and microbial effects. *Semin Orthod* 2014;20:139–49.
- Low B, Lee W, Seneviratne CJ *et al*. Ultrastructure and morphology of biofilms on thermoplastic orthodontic appliances in 'fast' and 'slow' plaque formers. *Eur J Orthod* 2011;33:577–83. https://doi. org/10.1093/ejo/cjq126
- Tasios T, Papageorgiou SN, Papadopoulos MA *et al.* Prevention of orthodontic enamel demineralization: a systematic review with meta-analyses. *Orthod Craniofac Res*2019;22:225–35. https://doi. org/10.1111/ocr.12322
- Niazi FH, Kamran MA, Naseem M et al. Anti-plaque efficacy of herbal mouthwashes compared to synthetic mouthwashes in patients undergoing orthodontic treatment: a randomised controlled trial. Oral Health Prev Dent 2018;16:409–16. https:// doi.org/10.3290/j.ohpd.a40983
- Morelli L, Capurso L. FAO/WHO guidelines on probiotics: 10 years later. J Clin Gastroenterol 2012;46:S1–2. https://doi.org/10.1097/ mcg.0b013e318269fdd5
- Teughels W, Van Essche M, Sliepen I et al. Probiotics and oral healthcare. Periodontology 2000 2008;48:111–47. https://doi. org/10.1111/j.1600-0757.2008.00254.x
- 12. Santosa S, Farnworth E, Jones PJ. Probiotics and their potential health claims. *Nutr Rev* 2006;64:265–74. https://doi. org/10.1111/j.1753-4887.2006.tb00209.x
- 13. Twetman S, Keller MK. Probiotics for caries prevention and control. *Adv Dent Res* 2012;24:98–102.
- 14. Yanine N, Araya I, Brignardello-Petersen R et al. Effects of probiotics in periodontal diseases: a systematic review. Clin Oral Investig 2013;17:1627–34. https://doi.org/10.1007/s00784-013-0990-7
- 15. López-Valverde N, López-Valverde A, Macedo De Sousa B et al. Role of probiotics in halitosis of oral origin: a systematic review

and meta-analysis of randomized clinical studies. *Front Nutr* 2021;8:787908. https://doi.org/10.3389/fnut.2021.787908

- Pahumunto N, Piwat S, Chankanka O *et al*. Reducing mutans streptococci and caries development by *Lactobacillus paracasei* SD1 in preschool children: a randomized placebo-controlled trial. *Acta Odontol Scand* 2018;76:331–7. https://doi.org/10.1080/0001 6357.2018.1453083
- Vicario M, Santos A, Violant D et al. Clinical changes in periodontal subjects with the probiotic *Lactobacillus reuteri* Prodentis: a preliminary randomized clinical trial. *Acta Odontol Scand* 2013;71:813–9. https://doi.org/10.3109/00016357.2012.734404
- Lee DS, Lee SA, Kim M *et al.* Reduction of halitosis by a tablet containing Weissella cibaria CMU: a randomized, double-blind, placebo-controlled study. J Med Food 2020;23:649–57. https://doi. org/10.1089/jmf.2019.4603
- Goyal N, Shamanna PU, Varughese ST *et al.* Effects of amine fluoride and probiotic mouthwash on levels of *Porphyromonas gingivalis* in orthodontic patients: a randomized controlled trial. J *Indian Soc Periodontol* 2019;23:339–44. https://doi.org/10.4103/ jisp_jisp_551_18
- Benic GZ, Farella M, Morgan XC *et al.* Oral probiotics reduce halitosis in patients wearing orthodontic braces: a randomized, tripleblind, placebo-controlled trial. *J Breath Res* 2019;13:036010. https://doi.org/10.1088/1752-7163/ab1c81
- 21. Shah SS, Nambiar S, Kamath D *et al.* Comparative evaluation of plaque inhibitory and antimicrobial efficacy of probiotic and chlorhexidine oral rinses in orthodontic patients: a randomized clinical trial. *Int J Dent* 2019;2019:1964158. https://doi. org/10.1155/2019/1964158
- 22. Megha S, Shalini G, Varsha SA *et al.* Effect of short-term placebocontrolled consumption of probiotic yoghurt and Indian curd on the streptococcus mutans level in children undergoing fixed interceptive orthodontic therapy. *Turk J Orthod* 2019;32:16–21. https://doi.org/10.5152/TurkJOrthod.2019.18016
- 23. Hadj-Hamou R, Senok AC, Athanasiou AE *et al.* Do probiotics promote oral health during orthodontic treatment with fixed appliances? A systematic review. *BMC Oral Health* 2020;20:126. https://doi.org/10.1186/s12903-020-01109-3
- 24. Pietri FK, Rossouw PE, Javed F et al. Role of probiotics in oral health maintenance among patients undergoing fixed orthodontic therapy: a systematic review of randomized controlled clinical trials. Probiotics Antimicrob Proteins 2020;12:1349–59. https:// doi.org/10.1007/s12602-020-09683-2
- 25. Dadgar S, Heydarian A, Sobouti F et al. Effects of probiotic and fluoride mouthrinses on *Streptococcus mutans* in dental plaque around orthodontic brackets: a preliminary explorative randomized placebo-controlled clinical trial. *Dent Res J* 2021;18:74. https:// doi.org/10.4103/1735-3327.326647
- 26. Ebrahim F, Malek S, James K *et al.* Effectiveness of the lorodent probiotic lozenge in reducing plaque and *Streptococcus mutans* levels in orthodontic patients: a double-blind randomized control trial. *Front Oral Health* 2022;3:884683.
- Alforaidi S, Bresin A, Almosa N et al. Effect of drops containing Lactobacillus reuteri (DSM 17938 and ATCC PTA 5289) on plaque acidogenicity and other caries-related variables in orthodontic patients. BMC Microbiol 2021;21:271. https://doi.org/10.1186/ s12866-021-02310-2
- Guyatt GH, Oxman AD, Vist GE *et al.*; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008;336:924–6. https://doi. org/10.1136/bmj.39489.470347.AD
- Kohar NM, Emmanuel V, Astuti L. Comparison between probiotic lozenges and drinks towards periodontal status improvement of orthodontic patients. *Dent J (Majalah Kedokteran Gigi)* 2015;48:126–9.
- Jivraj FE. Effectiveness of the Lorodent Probiotic Lozenge in Reducing Plaque and S. Mutans Levels in Orthodontic Patients: a Randomized, Double-Blind, Placebo-Controlled Trial. Canada: University of Toronto, 2015.

- 31. Habib S. Assessment of the Therapeutic Potential of a Dental Probiotic in Orthodontic Patients Affected by Gingivitis: A Randomized Control Trial. Canada: University of Toronto, 2016.
- 32. Gizani S, Petsi G, Twetman S *et al.* Effect of the probiotic bacterium *Lactobacillus reuteri* on white spot lesion development in orthodontic patients. *Eur J Orthod* 2016;38:85–9. https://doi. org/10.1093/ejo/cjv015
- 33. Pinto GS, Cenci MS, Azevedo MS et al. Effect of yogurt containing Bifidobacterium animalis subsp. lactis DN-173010 probiotic on dental plaque and saliva in orthodontic patients. Caries Res 2014;48:63–8. https://doi.org/10.1159/000353467
- 34. Alp S, Baka ZM. Effects of probiotics on salivary Streptecoccus mutans and Lactobacillus levels in orthodontic patients. Am J Orthod Dentofacial Orthop 2018;154:517–23.
- 35. Jose JE, Padmanabhan S, Chitharanjan AB. Systemic consumption of probiotic curd and use of probiotic toothpaste to reduce *Streptococcus mutans* in plaque around orthodontic brackets. *Am J Orthod Dentofacial Orthop* 2013;144:67–72. https://doi. org/10.1016/j.ajodo.2013.02.023
- 36. Cildir SK, Germec D, Sandalli N *et al.* Reduction of salivary mutans streptococci in orthodontic patients during daily consumption of yoghurt containing probiotic bacteria. *Eur J Orthod* 2009;31:407– 11. https://doi.org/10.1093/ejo/cjn108
- 37. Kargul B, Caglar E, Lussi A. Erosive and buffering capacities of yogurt. *Quintessence Int* 2007;38:381–5.
- Nadelman P, Magno MB, Masterson D et al. Are dairy products containing probiotics beneficial for oral health? A systematic review and meta-analysis. Clin Oral Investig 2018;22:2763–85. https://doi.org/10.1007/s00784-018-2682-9
- 39. Näse L, Hatakka K, Savilahti E et al. Effect of long-term consumption of a probiotic bacterium, *Lactobacillus rhamnosus* GG, in milk on dental caries and caries risk in children. *Caries Res* 2001;35:412–20. https://doi.org/10.1159/000047484
- 40. Stecksén-Blicks C, Sjöström I, Twetman S. Effect of long-term consumption of milk supplemented with probiotic lactobacilli and fluoride on dental caries and general health in preschool children: a cluster-randomized study. *Caries Res* 2009;43:374–81. https://doi. org/10.1159/000235581
- Timmerman HM, Koning CJ, Mulder L et al. Monostrain, multistrain and multispecies probiotics—A comparison of functionality and efficacy. Int J Food Microbiol 2004;96:219–33. https://doi.org/10.1016/j.ijfoodmicro.2004.05.012
- 42. Sudjalim TR, Woods MG, Manton DJ et al. Prevention of demineralization around orthodontic brackets in vitro. Am J Orthod Dentofacial Orthop 2007;131:705.e1–9. https://doi.org/10.1016/j. ajodo.2006.09.043
- 43. Rosenbloom RG, Tinanoff N. Salivary Streptococcus mutans levels in patients before, during, and after orthodontic treatment. Am J Orthod Dentofacial Orthop 1991;100:35–7. https://doi. org/10.1016/0889-5406(91)70046-Y
- 44. Tanabe Y, Park JH, Tinanoff N *et al.* Comparison of chairside microbiological screening systems and conventional selective media in children with and without visible dental caries. *Pediatr Dent* 2006;28:363–8.
- 45. Laleman I, Detailleur V, Slot DE *et al.* Probiotics reduce mutans streptococci counts in humans: a systematic review and metaanalysis. *Clin Oral Investig* 2014;18:1539–52. https://doi. org/10.1007/s00784-014-1228-z
- 46. Gruner D, Paris S, Schwendicke F. Probiotics for managing caries and periodontitis: Systematic review and meta-analysis. J Dent 2016;48:16–25. https://doi.org/10.1016/j.jdent.2016.03.002
- 47. Haukioja A, Yli-Knuuttila H, Loimaranta V *et al.* Oral adhesion and survival of probiotic and other lactobacilli and bifidobacteria in vitro. *Oral Microbiol Immunol* 2006;21:326–32. https://doi. org/10.1111/j.1399-302X.2006.00299.x
- Cosseau C, Devine DA, Dullaghan E et al. The commensal Streptococcus salivarius K12 downregulates the innate immune responses of human epithelial cells and promotes host-microbe homeostasis. Infect Immun 2008;76:4163–75. https://doi.org/10.1128/IAI.00188-08

- 49. Caglar E, Kuscu OO, Selvi Kuvvetli S et al. Short-term effect of icecream containing *Bifidobacterium lactis* Bb-12 on the number of salivary mutans streptococci and lactobacilli. *Acta Odontol Scand* 2008;66:154–8. https://doi.org/10.1080/00016350802089467
- 50. Caglar E, Kavaloglu SC, Kuscu OO et al. Effect of chewing gums containing xylitol or probiotic bacteria on salivary mutans

streptococci and lactobacilli. Clin Oral Investig 2007;11:425-9. https://doi.org/10.1007/s00784-007-0129-9

51. Caglar E, Cildir SK, Ergeneli S et al. Salivary mutans streptococci and lactobacilli levels after ingestion of the probiotic bacterium Lactobacillus reuteri ATCC 55730 by straws or tablets. Acta Odontol Scand 2006;64:314–8. https://doi.org/10.1080/00016350600801709